The Industry Standard: Intelligence for the Information Economy

  September 5, 2001
  NEWS & ANALYSIS
   Headlines
   Money & Markets
   Tech & Telecom
   Media & Marketing
   Metrics & Stats
   Policy & Politics
  SEARCH
   
  advanced search
  SERVICES
   Company Index
   Newsletters
   Wireless
  PRINT EDITION
   Read the Magazine

Home > Company Index > Drugs > Biotechnology-Medicine > BioMedicines, Inc.

BioMedicines, Inc.
 PROFILE
BioMedicines sniffs out the competition for its drugs. The development-stage company identifies potential drug candidates in other firms' pipelines, then buys the rights to products it believes can be developed more efficiently or toward different indications. Lead drug candidate Biomed 77, acquired from Schering AG, is in clinical trials as a potential treatment for metastatic breast cancer. Its pipeline also includes omega interferon (purchased from Boehringer Ingelheim), which is being developed to treat hepatitis B and C; and Biomed 101 (from G.D. Searle), which may have applications for AIDS, melanoma, or kidney cancer. CEO Mark Moran founded the firm in 1997.

 COMPETITION
Amgen Inc. (AMGN)
GMP Companies, Inc. (dossier)
Schering-Plough Corporation (SGP)

 FINANCIAL OVERVIEW
Fiscal Year-End: December
1999 Sales (mil.): 0.40
Employees: 16
Revenue per employee: $25,000.00

 KEY PEOPLE
• Mark Moran
    CEO
• James M. Ahlers
    CFO

 CONTACT INFO
1301 Marina Village Pkwy., Ste. 200
Alameda, CA 94501
US
Phone: 510-814-0112
Fax: 510-814-0170
Online: Web Site

Company Data   News, quotes & more       

Hoovers Online   Hoover's Company Capsule
Copyright © 2001, Hoover's Inc. Austin, Texas.
For changes and updates, contact Hoover's directly.


ADVERTISEMENT
FEATURED LINKS
Home |  Customer Service |  About Us
Australia |  Brazil |  China |  Korea |  Norway |  Poland |  Sweden |  Taiwan

Copyright ©2001 Standard Media International. Privacy Policy
Stock data provided by Stockpoint and its data suppliers. Copyright © 1995-2001